- Home
- ASRT vs MCRB Comparison
ASRT vs MCRB Comparison
Compare ASRT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASRT | MCRB |
|---|---|---|
| Founded | 1995 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.0M | 85.7M |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ASRT | MCRB |
|---|---|---|
| Price | $21.62 | $7.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $18.00 | $14.00 |
| AVG Volume (30 Days) | ★ 244.2K | 43.7K |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $118,713,000.00 | $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.85 | N/A |
| P/E Ratio | ★ N/A | $12.03 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.58 | $6.56 |
| 52 Week High | $20.45 | $29.98 |
Technical Indicators
Market Signals| Indicator | ASRT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 84.89 | 40.36 |
| Support Level | $0.70 | N/A |
| Resistance Level | N/A | $9.53 |
| Average True Range (ATR) | 0.13 | 0.57 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 97.30 | 45.49 |
Price Performance
Historical ComparisonAbout ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.